Heparin therapy in COVID-19: Call for randomized controlled trials (RCTs)Article Published on 2022-09-172023-07-10 Journal: Bioscience trends [Category] COVID19(2023년), [키워드] Blood coagulation Coronavirus infection COVID-19 fibrin degradation products heparin [DOI] 10.5582/bst.2022.01225
Kinetic and Structural Aspects of Glycosaminoglycan-Monkeypox Virus Protein A29 Interactions Using Surface Plasmon ResonanceArticle Published on 2022-09-112023-06-10 Journal: Molecules [Category] Fulltext, 원숭이두창, [키워드] A29 chondroitin sulfate dermatan sulfate heparin Monkeypox virus surface plasmon resonance [DOI] 10.3390/molecules27185898 PMC 바로가기
An extracellular matrix biosensing mimetic for evaluating cathepsin as a host target for COVID-19Research article Published on 2022-09-012022-10-05 Journal: Analytica chimica acta [Category] SARS, 변종, 치료기술, 치료제, [키워드] cathepsin chronic inflammation combating COVID-19 COVID-19 virus Cu detect disease ECM evaluate Extracellular matrix heparin Host limit of detection mimicking Mutation Neutralizing new virus Patient Protein Quantitative analysis seeking targets virus [DOI] 10.1016/j.aca.2022.340267 [Article Type] Research article
Circulating histones contribute to monocyte and MDW alterations as common mediators in classical and COVID-19 sepsisArticle Published on 2022-08-302022-11-15 Journal: Critical Care [Category] 진단, [키워드] alteration assessment Biomarkers blood cell breadth Cell change Characteristics circulating classical contribute COVID-19 COVID-19 sepsis Critical care critical condition cytoplasmic death demonstrated distribution DNA drug extracellular trap granularity healthy healthy control heparin higher risk highlighting histone Histones in vitro in vivo Inflammatory involved key factor laboratory feature measurement Modification modulating monocyte Monocyte distribution width neutralization nuclear Pathologies Pathways Patient patients with COVID-19 procoagulant activity Prominent Protein Regulation released Sepsis sepsis patients severity significant increase subject thrombosis treated Treatment vacuolization Volume Whole blood whole blood sample [DOI] 10.1186/s13054-022-04138-2 PMC 바로가기
Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity세포 표면 SARS-CoV-2 뉴클레오캡시드 단백질은 선천성 및 후천성 면역을 조절합니다Article Published on 2022-08-052022-09-11 Journal: Science Advances [Category] SARS, 변종, 치료기술, 치료법, 치료제, [키워드] activate adaptive antibody antigenicity bind Cell cell surface cells chemokine chemokines chemotaxis Combination conserved CoVs cross-reactive cytosol detect electrostatic heparan sulfate heparin high affinity high-affinity binding human CoVs immune cells Immunity induce infected cells inhibited Innate immune cells Innate immunity leukocyte leukocytes live cells MERS-CoV modulate neighboring cell neighboring cells nucleocapsid protein Protein released SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 nucleocapsid SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2-infected cell SARS-CoV-2-infected cells sequestering Strains sulfate sulfated T cell T cell responses transfected cell Vaccine zoonotic [DOI] 10.1126/sciadv.abp9770 PMC 바로가기 [Article Type] Article
Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administrationIV ChAdOx1 nCov-19 투여 후 혈소판 감소증 및 비장 혈소판 유도 면역 반응Article Published on 2022-08-042022-09-11 Journal: Blood [Category] SARS, 치료기술, 치료제, [키워드] accompanied acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adenovirus adenovirus vaccine adenovirus-based administration aggregate anatomic sites antibody antiplatelet antiplatelet antibody approach Autoimmune response Autoimmunity B-cell response binding ChAdOx1 ChAdOx1 nCoV-19 characterized circulating antibodies circulating antibody clinical entities Complication contribute coronavirus followed by glycoprotein heparin heparin-induced thrombocytopenia highlight immune response Immune thrombocytopenia in vitro in vivo model Intramuscular injection IV injection Macrophage macrophages marginal zone mechanism mice pathology Patient phagocytosed Platelet platelet activation platelet factor 4 Platelets potential mechanism prothrombotic state receptor SARS-CoV-2 severe acute respiratory syndrome Coronavirus spleen thrombocytopenia thrombosis Trigger vaccination Vaccine zone [DOI] 10.1182/blood.2021014712 PMC 바로가기 [Article Type] Article
Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods철저한 구조 기반 가상 스크리닝, 분자 역학 시뮬레이션을 사용하여 B.1.617.2(델타), AY.1(델타 플러스) 및 C.37(람다) SARS-CoV-2 변이체에서 중요한 스파이크 돌연변이를 타겟팅하기 위한 전산 용도 변경 접근 방식 및 MM-PBSA 방법Article Published on 2022-08-012022-09-11 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종, 신약개발, [키워드] ACE-2 acute respiratory syndrome acute respiratory syndrome coronavirus angiotensin angiotensin-converting enzyme 2 approach Area atovaquone AY.1 B.1.617.2 binding affinity binding site candidate causative agent complex complexes Compound contagious contribute coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical Delta delta variant Delta variants docking result docking results drug Drug repurposing drug-likeness drugs eight enzyme FDA approved drug FDA approved Drugs followed by genomic help heparin highest binding affinity Host hydrogen Hydrogen bond identify in silico inhibiting inhibitor inhibitors interact Interaction interactions Lambda Ligand MD simulation MD simulations molecular molecular docking molecular dynamics Molecular dynamics simulation Molecular mechanics morbidity and mortality mortality rates Mutation mutations Praziquantel Protein Proteins RBD Receptor-binding domain reported Research researcher residue SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 variant selected severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Simulation spike spike mutation Spike protein stability surface surface area targets the receptor-binding domain the spike protein variant variants variants of concern viral cell Virtual screening VoC was done was performed wild type Wuhan Wuhan, China [DOI] 10.1016/j.compbiomed.2022.105709 PMC 바로가기 [Article Type] Article
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection급성 COVID-19 감염의 주요 증상인 자발적 헤파린 유발 혈소판 감소증으로 인한 사지 허혈Case Reports Published on 2022-08-012022-09-12 Journal: Journal of Thrombosis and Thrombolysis [Category] MERS, 진단, [키워드] 2019 coronavirus disease absence activate acute COVID-19 addition administration antibodies characterized complexes COVID-19 develop enzyme-linked immunosorbent had no heparin Hospitalization IgG antibody immunoglobulins, intravenous Infection instances Intravenous immunoglobulin Ischemia less male occur Pain Patient PF4 Platelet platelet activation positive presenting prothrombotic condition reported Serotonin Spontaneous spontaneous heparin-induced thrombocytopenia SRA syndrome thrombocytopenia thrombosis treated Vaccinations [DOI] 10.1007/s11239-022-02676-8 PMC 바로가기 [Article Type] Case Reports
Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective studyObservational Study Published on 2022-08-012022-10-05 Journal: The American journal of emergency medicine [Category] 임상, [키워드] administration adverse event Anticoagulant anticoagulation association Care Characteristics Coronavirus disease 2019 COVID-19 Critical care disease early administration early phase ECMO Effect extracorporeal membrane oxygenation group groups heparin hospital ICU in-hospital mortality in-hospital mortality rate intensive care intensive care unit Japan mechanical ventilation multivariate model outcome Oxygen therapy Patient Pneumonia retrospective Retrospective study secondary outcome severe coronavirus disease severe COVID-19 patient Severe COVID-19 pneumonia significantly significantly lower systemic anticoagulation therapeutic therapeutic anticoagulation therapy unfractionated heparin ventilator-free day VFD [DOI] 10.1016/j.ajem.2022.05.031 PMC 바로가기 [Article Type] Observational Study
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialClinical Trial Published on 2022-08-012022-10-05 Journal: The Lancet. Haematology [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 95% CI acute COVID-19 adjusted relative risk age Anti-inflammatory effects Antithrombotic antiviral properties assigned assumption Berlin body temperature clinically Control control group COVID-19 criteria death Efficacy eight eligible enoxaparin event rates foundation futility Germany heparin hospitalisation independent initial intention-to-treat population interim analysis investigator-initiated IQR Johanna major bleeding major bleeding event median age multicentre nine not reduce Older older patient Open-label outcome Outpatient parallel-group participant phase 3 trial Prevent Primary outcome Probability prothrombotic randomisation randomised Randomly receive Registered reported respiratory infection respiratory symptom risk Safety Monitoring Board Serious Adverse Event Standard of care statistical Study design study population Switzerland symptomatic Thromboprophylaxis Treatment Trial university University of Zurich was done were recorded with COVID-19 women [DOI] 10.1016/S2352-3026(22)00175-2 PMC 바로가기 [Article Type] Clinical Trial